| Cat.No. | Name | Information |
|---|---|---|
| M8623 | RSV604 (A-60444) | RSV604 (A-60444) is a cell-permeable, non-cytotoxic (CC50 >50 μM) benzodiazepine derivative that is reported to target respiratory syncytial virus (RSV) nucleoprotein (N), with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM). |
| M30271 | BMS-433771 dihydrochloride hydrate | BMS-433771 dihydrochloride hydrate is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 dihydrochloride hydrate is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 dihydrochloride hydrate can be used for the research of respiratory tract disease. |
| M29010 | Sisunatovir hydrochloride | Sisunatovir (RV521) hydrochloride, an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively. |
| M29006 | PC786 | PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM). |
| M28451 | ALS-8112 | ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM. |
| M28390 | Ziresovir | Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species. |
| M28174 | Enzaplatovir | Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection. |
| M25247 | Motavizumab | Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research. |
| M25160 | Clesrovimab | Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection. |
| M24783 | Felvizumab | Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV. |
| M24752 | Suptavumab | Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection. |
| M24593 | Gontivimab | Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung. |
| M21280 | Rilematovir (JNJ-53718678) | Rilematovir (JNJ-53718678) is a potent and orally available fusion inhibitor of the RSV virus, optimized from a prior oral inhibitor, BMS-433771. |
| M21128 | Sisunatovir | Sisunatovir (RV521) is an oral RSV fusion (RSV-F) protein inhibitor with strong efficacy against a panel of clinically isolated RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM for RSV-A and RSV-B isolates, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
